VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Wednesday. The firm issued a sell rating on the stock.

Several other analysts have also weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research note on Wednesday, January 8th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Down 2.2 %

Shares of VNRX opened at $0.63 on Wednesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The firm has a market cap of $58.21 million, a price-to-earnings ratio of -1.74 and a beta of 1.20. The stock has a 50 day moving average of $0.65 and a 200-day moving average of $0.66.

Insiders Place Their Bets

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction dated Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 358,266 shares of company stock valued at $204,212 over the last three months. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.